Pancuronium (United States and Canada: Not available): Drug information

(For additional information see "Pancuronium (United States and Canada: Not available): Patient drug information" and see "Pancuronium (United States and Canada: Not available): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

ALERT: US Boxed Warning

Experienced personnel:

This drug should be administered by adequately trained individuals familiar with its actions, characteristics, and hazards.

Pharmacologic Category

Neuromuscular Blocker Agent, Nondepolarizing

Dosing: Adult

Note: Dose to effect; doses will vary due to interpatient variability. Ensure adequate pain control and sedation prior to and during administration of neuromuscular blockade to achieve deep sedation (SCCM [Murray 2016]).

Mechanically ventilated patients during surgery, neuromuscular blockade

Mechanically ventilated patients during surgery, neuromuscular blockade (alternative agent) (adjunctive therapy):

Note : Inhaled anesthetic agents and succinylcholine prolong the duration of action of pancuronium. Use lower end of the dosing range; redosing interval guided by monitoring with a peripheral nerve stimulator.

IV: Loading dose of 0.04 to 0.12 mg/kg; may repeat with 0.01 to 0.02 mg/kg according to desired clinical response (Gropper 2020; manufacturer’s labeling).

Mechanically ventilated patients in the ICU, neuromuscular blockade

Mechanically ventilated patients in the ICU, neuromuscular blockade (alternative agent) (off-label use):

Note: May use to facilitate mechanical ventilation (eg, moderate to severe acute respiratory distress syndrome), for refractory, life-threatening status asthmaticus, or for shivering from therapeutic hypothermia (Alhazzani 2020; SCCM [Murray 2016]; SSC [Evans 2021]).

IV: Loading dose of 0.05 to 0.1 mg/kg; followed by 0.02 to 0.05 mg/kg every 1 to 4 hours according to desired clinical response and/or peripheral nerve stimulation (deBacker 2017; de Lemos 1999; Greenberg 2013; Murray 1995; SCCM [Murray 2002]).

Dosing: Kidney Impairment: Adult

Elimination half-life is doubled, plasma clearance is reduced and rate of recovery is sometimes much slower. There are no dosage adjustments provided in the manufacturer’s labeling; however, the following adjustments have been recommended (Aronoff 2007):

CrCl >50 mL/minute: No dosage adjustment necessary.

CrCl 10 to 50 mL/minute: Administer 50% of normal dose.

CrCl <10 mL/minute: Avoid use.

Hemodialysis/peritoneal dialysis: Avoid use.

CRRT: Administer 50% of normal dose.

Dosing: Hepatic Impairment: Adult

Elimination half-life is doubled, plasma clearance is doubled, recovery time is prolonged, volume of distribution is increased (50%) and results in a slower onset, higher total dosage, and prolongation of neuromuscular blockade. Patients with liver disease may develop slow resistance to nondepolarizing muscle relaxant. Large doses may be required and problems may arise in antagonism.

Dosing: Obesity: Adult

Ideal body weight or adjusted body weight is recommended when calculating dose for obese patients (SCCM [Murray 2016]).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Pancuronium (United States and Canada: Not available): Pediatric drug information")

Note: Dosing in obese patients should be calculated using ideal body weight (Playfor 2007):

Neuromuscular blockade

Neuromuscular blockade:

Intermittent IV (Martin 1999; Playfor 2007):

Infants: 0.05 to 0.1 mg/kg/dose as needed (usually every 4 to 6 hours).

Children and Adolescents: 0.05 to 0.15 mg/kg/dose as needed (usually every 4 to 6 hours).

Continuous IV infusion: Infants, Children, and Adolescents: Initial: 0.8 mcg/kg/minute (0.05 mg/kg/hour); titrate infusion by 0.2 mcg/kg/minute (0.01 mg/kg/hour) to maintain one to two twitches of train of four; usual range: 0.8 to 1.3 mcg/kg/minute (0.05 to 0.08 mg/kg/hour); higher doses were reported in patients receiving concomitant antiseizure medications or requiring infusions ≥5 days; dosing based on a prospective open-label study in 25 pediatric patients (mean age: 4.3 ± 4.9 years [range: 3 months to 17 years]) (Fuhrman 2017; Tobias 1995).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, the elimination half-life is doubled, plasma clearance is reduced, and rate of recovery is sometimes much slower in patients with renal failure. The following adjustments have been recommended (Aronoff 2007):

Infants, Children, and Adolescents: Note: Renally adjusted dose recommendations are based on doses of 0.1 to 0.2 mg/kg/dose every 2 to 4 hours or 0.5 to 1 mcg/kg/minute.

GFR >50 mL/minute/1.73 m²: No dosage adjustment necessary.

GFR 10 to 50 mL/minute/1.73 m²: Administer 50% of normal dose.

GFR <10 mL/minute/1.73 m²: Avoid use.

Intermittent hemodialysis: Avoid use.

Peritoneal dialysis (PD): Avoid use.

Continuous renal replacement therapy (CRRT): Administer 50% of normal dose; titrate to effect.

Dosing: Hepatic Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Elimination half-life is doubled, plasma clearance is decreased, recovery time is prolonged, and volume of distribution is increased (50%) in patients with liver disease. This results in a slower onset, higher total dosage, and prolongation of neuromuscular blockade; use with caution and monitor closely. Patients with liver disease may develop slow resistance to nondepolarizing muscle relaxant. Large doses may be required and problems may arise in antagonism.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Flushing, increased blood pressure, increased cardiac work, increased pulse, severe myasthenia (long-term use)

Central nervous system: Paralysis (long-term use)

Dermatologic: Skin rash (transient)

Gastrointestinal: Sialorrhea

<1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, bronchospasm, erythema, hypersensitivity reaction, hypotension, tachycardia

Contraindications

Hypersensitivity to pancuronium, bromide, or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylaxis: Severe anaphylactic reactions have been reported (some life-threatening and fatal). Appropriate emergency treatment (including epinephrine 1 mg/mL) should be immediately available during use. Use caution in patients with previous anaphylactic reactions to other neuromuscular blocking agents.

Disease-related concerns:

• Burn injury: Resistance may occur in burn patients (≥20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).

• Conditions that may antagonize neuromuscular blockade (decreased paralysis): Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Gropper 2020; Naguib 2002).

• Conditions that may potentiate neuromuscular blockade (increase paralysis): Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Gropper 2020; Naguib 2002).

• Hepatic impairment: Elimination half-life is doubled due to reduced clearance of pancuronium and recovery is prolonged; use with caution in patients with hepatic impairment and adjust dose appropriately.

• Kidney impairment: Elimination half-life is doubled due to reduced clearance of pancuronium and recovery is prolonged; use with caution in patients with kidney impairment and adjust dose appropriately.

Special populations:

• Older adults: Use with caution in older adults; effects and duration are more variable.

• Immobilized patients: Resistance may occur in patients who are immobilized.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

Other warnings/precautions:

• Appropriate use: Maintenance of an adequate airway and respiratory support is critical. All patients should receive eye care including liberal use of lubricating drops, gel, or ointment and eyelids should remain closed during continuous neuromuscular blockade to protect against damage to the cornea (ulceration and drying).

• Experienced personnel: [US Boxed Warning]: Should be administered by adequately trained individuals familiar with its use.

• Risk of medication errors: Accidental administration may be fatal. Confirm proper selection of intended product, store vial so the cap and ferrule are intact and the possibility of selecting the wrong product is minimized, and ensure that the intended dose is clearly labeled and communicated, when applicable.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous, as bromide:

Generic: 1 mg/mL (10 mL [DSC])

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Pancuronium Bromide Intravenous)

1 mg/mL (per mL): $0.69

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous, as bromide:

Generic: 1 mg/mL ([DSC])

Administration: Adult

IV: May be administered undiluted by rapid IV injection.

Administration: Pediatric

Parenteral:

IV push: Administer undiluted by rapid IV injection.

Continuous IV Infusion: Further dilute in an appropriate fluid and administer via an infusion pump.

Use: Labeled Indications

Mechanically ventilated patients during surgery, neuromuscular blockade: As an adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery or mechanical ventilation.

Note: Neuromuscular blockade does not provide pain control, sedation, or amnestic effects. Appropriate analgesic and sedative mediations should be used before and during administration of neuromuscular blockade to achieve deep sedation.

Use: Off-Label: Adult

Mechanically ventilated patients in the ICU, neuromuscular blockade

Medication Safety Issues

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Other safety concerns:

According to the 2020 to 2021 ISMP Targeted Medication Safety Best Practices for Hospitals, neuromuscular blockers should be segregated, sequestered, and differentiated from all other medication wherever they are stored. This includes:

Only storing in places within the hospital that they are routinely used.

Placing in sealed boxes or in rapid sequence intubation kits (preferred).

Limiting availability in automated dispensing cabinets to perioperative, labor and delivery, critical care, and emergency departments only.

Placing in separate lidded containers within the pharmacy refrigerator or other isolated pharmacy storage area.

Affixing an auxiliary label to clearly communicate respiratory paralysis will occur and ventilation required on all storage bins and/or automated dispensing pockets/drawers (exception anesthesia-prepared syringes) stating one of the following:

Warning: Causes Respiratory Arrest – Patient Must Be Ventilated

Warning: Paralyzing Agent – Causes Respiratory Arrest

Warning: Causes Respiratory Paralysis – Patient Must Be Ventilated

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Aminoglycosides: May enhance the therapeutic effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy

Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and colistimethate. Risk D: Consider therapy modification

Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments Risk D: Consider therapy modification

CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Management: When initiating a non-depolarizing neuromuscular blocking agent (NMBA) in a patient receiving an inhalational anesthetic, initial NMBA doses should be reduced 15% to 25% and doses of continuous infusions should be reduced 30% to 60%. Risk D: Consider therapy modification

Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C: Monitor therapy

Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C: Monitor therapy

Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported. Risk C: Monitor therapy

Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of neuromuscular-blocking agents and polymyxin B. If concomitant use cannot be avoided, monitor for deeper, prolonged neuromuscular-blocking effects (eg, respiratory paralysis) in patients receiving this combination. Risk D: Consider therapy modification

Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk X: Avoid combination

Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Theophylline Derivatives: May enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Pregnancy Considerations

Small amounts of pancuronium cross the placenta (Daily 1984). May be used short-term in cesarean section; reduced doses recommended in patients also receiving magnesium sulfate due to enhanced effects.

Monitoring Parameters

Vital signs (heart rate, blood pressure, respiratory rate); degree of muscle paralysis (eg, presence of spontaneous movement, ventilator asynchrony, shivering, and consider use of a peripheral nerve stimulator with train of four monitoring along with clinical assessments).

In the ICU setting, limit the duration of paralysis and provide a physiotherapy regimen in patients requiring continuous paralysis (SCCM [Murray 2016]).

Mechanism of Action

Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites

Pharmacokinetics (Adult Data Unless Noted)

Onset of effect:

Infants: 2 to 5 minutes, Children: 2 to 4 minutes (Martin 1999).

Adults: 2 to 5 minutes (Price 2012).

Duration (dose dependent):

Pediatric (Meretoja 1990): IV:

Duration:

Neonates 38 to 41 weeks GA (based on mean ED₅₀ [0.039 mg/kg]): 56 minutes.

Infants 3 to 11 months (based on mean ED₅₀[0.037 mg/kg]): 57 minutes.

Children 3 to 9 years (based on mean ED₅₀ [0.052 mg/kg]): 53 minutes.

Adolescents 12 to 16 years (based on mean ED₅₀ [0.044 mg/kg]): 62 minutes.

Recovery time to 25% of control:

Neonates 38 to 41 weeks GA (based on mean ED₅₀ [0.039 mg/kg]): 16.6 ± 3.2 minutes.

Infants 3 to 11 months (based on mean ED₅₀[0.037 mg/kg]): 19.2 ± 2.9 minutes.

Children 3 to 9 years (based on mean ED₅₀ [0.052 mg/kg]): 18.8 ± 0.9 minutes.

Adolescents 12 to 16 years (based on mean ED₅₀ [0.044 mg/kg]): 16.1 ± 1.2 minutes.

Adults (time to recovery to 25% of control): 60 to 180 minutes (Greenburg 2013; McManus 2001; Murray 2002; Warr 2011); hypothermia may prolong the duration of action.

Distribution: V_d: 0.24 to 0.28 L/kg.

Protein binding: 87%.

Metabolism: Hepatic (30% to 45%); active metabolite 3-hydroxypancuronium (¹/₃ to ¹/₂ the activity of parent drug) (Murray 2002).

Half-life elimination: 89 to 161 minutes.

Excretion: Urine (40% to 70%); bile (10% to 15%) (Murray 2002; Price 2012).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: In patients with kidney failure, elimination half-life doubles, plasma clearance is reduced 60%, and V_d may be elevated and variable.

Hepatic function impairment: In patients with cirrhosis, the Vd increases ~50%, plasma clearance decreases 22%, and elimination half-life doubles.

Biliary obstruction: Plasma clearance decreases 50%, Vd increases ~50%, and elimination half-life doubles.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Pavulon;
(AR) Argentina: Bemicin | Pancuron | Pancuronio bromuro | Pancuronio gray | PANCURONIO HLB | Pavulon;
(AT) Austria: Pavulon;
(AU) Australia: Pavulon;
(BD) Bangladesh: Pavulon;
(BR) Brazil: Brometo de pancuronio;
(CH) Switzerland: Pavulon;
(CN) China: Pancuronium | Pavulon;
(CO) Colombia: Bromurex | Bromuro de pancuronio | Bromuro pancuronio | Pancuronio | Pavulon;
(CZ) Czech Republic: Pavulon;
(DE) Germany: Pancuronium | Pancuronium ratiopharm | Pancuroniumbromid panpharma | Pancuroniumbromid rotexmedica;
(EC) Ecuador: Pavulon;
(EE) Estonia: Pancuromium | Pavulon;
(EG) Egypt: Laxacurium | Pancuronium | Pavulon;
(ES) Spain: Pavulon;
(FI) Finland: Pavulon;
(FR) France: Pavulon;
(GB) United Kingdom: Pancuronium | Pavulon;
(GR) Greece: Pancuronium Inresa | Pavulon;
(HU) Hungary: Pavulon;
(ID) Indonesia: Pavulon;
(IE) Ireland: Pancuronium | Pavulon;
(IN) India: Pavulon;
(IT) Italy: Pavulon;
(JO) Jordan: Alpax;
(JP) Japan: Mioblock;
(KR) Korea, Republic of: Mioblock | Panslran | Unacron;
(LB) Lebanon: Pavulon;
(MA) Morocco: Pavulon;
(MX) Mexico: Bromurex;
(MY) Malaysia: Pancuronium bromide fresenius | Pavulon;
(NG) Nigeria: Pancuronium;
(NL) Netherlands: Pavulon;
(NO) Norway: Pancuronium | Pancuronium ahn | Pancuronium campus | Pancuronium Inresa | Pavulon;
(NZ) New Zealand: Pancuronium bromid;
(PH) Philippines: Pancuronium hydroxide bromide | Pavulon;
(PK) Pakistan: Pancron;
(PL) Poland: Pancuronium | Pavulon;
(PR) Puerto Rico: Pancuronium br;
(PT) Portugal: Pancuronio | Pancurox;
(QA) Qatar: Alpax;
(SA) Saudi Arabia: Alpax | Pavulon;
(SE) Sweden: Pavulon;
(SI) Slovenia: Pavulon;
(SK) Slovakia: Pavulon;
(TN) Tunisia: Pavulon;
(TR) Turkey: Pavulon;
(TW) Taiwan: Pancuronium | Pavulon;
(UG) Uganda: Pancuronium bromide fresenius;
(UY) Uruguay: Pancuronio bromuro;
(VE) Venezuela, Bolivarian Republic of: Pavulon;
(ZA) South Africa: Pancuronium bromide fresenius

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
Alhazzani W, Belley-Cote E, Møller MH, et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. Intensive Care Med. 2020;46(11):1977-1986. doi:10.1007/s00134-020-06227-8 [PubMed 33104824]
Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
Costarino AT, Polin RA. Neuromuscular relaxants in the neonate. Clin Perinatol. 1987;14(4):965-989. [PubMed 2827933]
Dailey PA, Fisher DM, Shnider SM, et al, "Pharmacokinetics, Placental Transfer, and Neonatal Effects of Vecuronium and Pancuronium Administered During Cesarean Section," Anesthesiology, 1984, 60(6):569-74. [PubMed 6145374]
deBacker J, Hart N, Fan E. Neuromuscular blockade in the 21st century management of the critically ill patient. Chest. 2017;151(3):697-706. doi:10.1016/j.chest.2016.10.040 [PubMed 27818334]
de Lemos JM, Carr RR, Shalansky KF, Bevan DR, Ronco JJ. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit Care Med. 1999;27(12):2648-2655. doi:10.1097/00003246-199912000-00007 [PubMed 10628604]
Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337 [PubMed 34605781]
Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 5th ed. Philadelphia, PA: Elsevier Health; 2017.
Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med. 2013;41(5):1332-1344. doi:10.1097/CCM.0b013e31828ce07c [PubMed 23591211]
Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K. Miller’s Anesthesia, 9th ed. Churchill Livingstone, 2020.
Han TH, Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. Br J Anaesth. 2009;102(1):55-60. [PubMed 19029093]
"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
Kumar P, Denson SE, Mancuso TJ, et al, "Premedication for Nonemergency Endotracheal Intubation in the Neonate," Pediatrics, 2010, 125(3):608-15. [PubMed 20176672]
Martin LD, Bratton SL, O'Rourke PP. Clinical uses and controversies of neuromuscular blocking agents in infants and children. Crit Care Med. 1999;27(7):1358-1368. [PubMed 10446832]
McManus MC. Neuromuscular blockers in surgery and intensive care, part 1. Am J Health Syst Pharm. 2001;58(23):2287-2299. doi:10.1093/ajhp/58.23.2287 [PubMed 11763807]
Meretoja OA, Taivainen T, Jalkanen L, et al, “Synergism Between Atracurium and Vecuronium in Infants and Children During Nitrous Oxide-Oxygen-Alfentanil Anaesthesia,” Br J Anaesth, 1994, 73(5):605-7. [PubMed 7826787]
Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508. [PubMed 25147175]
Murray MJ, Coursin DB, Scuderi PE, et al. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. Crit Care Med. 1995;23(3):450-458. doi:10.1097/00003246-199503000-00007 [PubMed 7874894]
Murray MJ, Cowen J, DeBlock H, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30(1):142-156. doi:10.1097/00003246-200201000-00021 [PubMed 11902255]
Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079-2103. doi: 10.1097/CCM.0000000000002027. [PubMed 27755068]
Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. Anesthesiology. 2002;96(1):202-31. [PubMed 11753022]
Pancuronium bromide Injection [prescribing information]. Lake Forest, IL: Hospira Inc; January 2019.
Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. Paediatr Anaesth. 2007;17(9):881-887. [PubMed 17683408]
Price D, Kenyon NJ, Stollenwerk N. A fresh look at paralytics in the critically ill: real promise and real concern. Ann Intensive Care. 2012;2(1):43. doi:10.1186/2110-5820-2-43 [PubMed 23062076]
Siegel MD. Acute respiratory distress syndrome: Supportive care and oxygenation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed February 15, 2018.
Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Order Entry System [published correction appears in Hosp Pharm. 2007; 42:84-85]. Hosp Pharm. 2006;41:1102-1106.
Tobias JD, Lynch A, McDuffee A, Garrett JS. Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit. Anesth Analg. 1995;81(1):13-16. [PubMed 7598240]
Warr J, Thiboutot Z, Rose L, Mehta S, Burry LD. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother. 2011;45(9):1116-1126. doi:10.1345/aph.1Q004 [PubMed 21828347]

Topic 9738 Version 194.0

خرید پکیج

Pancuronium (United States and Canada: Not available): Drug information